{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:47:00Z","timestamp":1786718820883,"version":"build-2736575974"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tzu Chi Med J"],"published-print":{"date-parts":[[2018]]},"DOI":"10.4103\/tcmj.tcmj_102_18","type":"journal-article","created":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T02:43:02Z","timestamp":1532486582000},"page":"204","source":"Crossref","is-referenced-by-count":3,"title":["Treatment strategies for neuromyelitis optica"],"prefix":"10.4103","volume":"30","author":[{"given":"Rong-Kung","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Lun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kung-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Kang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/1016-3190.237570-1","first-page":"1354","volume-title":"The case of the Marquis de Causan (1804): An early account of visual loss associated with spinal cord inflammation","author":"Jarius","year":"2012","journal-title":"J Neurol"},{"key":"key-10.4103\/1016-3190.237570-2","first-page":"2106","volume-title":"A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"key-10.4103\/1016-3190.237570-3","first-page":"1485","volume-title":"Revised diagnostic criteria for neuromyelitis optica","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"key-10.4103\/1016-3190.237570-4","first-page":"12","volume-title":"Clinical course of optic neuritis in patients with relapsing neuromyelitis optica","author":"Papais-Alvarenga","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"key-10.4103\/1016-3190.237570-5","first-page":"805","volume-title":"The spectrum of neuromyelitis optica","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol"},{"key":"key-10.4103\/1016-3190.237570-6","first-page":"629","volume-title":"Microcystic inner nuclear layer abnormalities and neuromyelitis optica","author":"Gelfand","year":"2013","journal-title":"JAMA Neurol"},{"key":"key-10.4103\/1016-3190.237570-7","first-page":"1406","volume-title":"In vivo identification of morphologic retinal abnormalities in neuromyelitis optica","author":"Sotirchos","year":"2013","journal-title":"Neurology"},{"key":"key-10.4103\/1016-3190.237570-8","first-page":"159","volume-title":"Optic neuritis in neuromyelitis optica","author":"Levin","year":"2013","journal-title":"Prog Retin Eye Res"},{"key":"key-10.4103\/1016-3190.237570-9","first-page":"476","volume-title":"Treatment of neuromyelitis optica","author":"Vodopivec","year":"2015","journal-title":"Curr Opin Ophthalmol"},{"key":"key-10.4103\/1016-3190.237570-10","first-page":"S33","volume-title":"Neuromyelitis optica: Potential roles for intravenous immunoglobulin","author":"Wingerchuk","year":"2013","journal-title":"J Clin Immunol"},{"key":"key-10.4103\/1016-3190.237570-11","first-page":"1268","volume-title":"Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an IgG-selective proteinase","author":"Tradtrantip","year":"2013","journal-title":"Mol Pharmacol"},{"key":"key-10.4103\/1016-3190.237570-12","first-page":"180","volume-title":"Treatment of neuromyelitis optica: Review and recommendations","author":"Kimbrough","year":"2012","journal-title":"Mult Scler Relat Disord"},{"key":"key-10.4103\/1016-3190.237570-13","first-page":"70","volume-title":"Present and future therapies in neuromyelitis optica spectrum disorders","author":"Kleiter","year":"2016","journal-title":"Neurotherapeutics"},{"key":"key-10.4103\/1016-3190.237570-14","doi-asserted-by":"crossref","unstructured":"Beck RW, Cleary PA, Anderson MM Jr., Keltner JL, Shults WT, Kaufman DI, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 1992;326:581-8.","DOI":"10.1056\/NEJM199202273260901"},{"key":"key-10.4103\/1016-3190.237570-15","first-page":"678","volume-title":"Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography","author":"Bennett","year":"2015","journal-title":"Mult Scler"},{"key":"key-10.4103\/1016-3190.237570-16","first-page":"1777","volume-title":"Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica","author":"Nakamura","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"key-10.4103\/1016-3190.237570-17","first-page":"1337","volume-title":"Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica","author":"Yamasaki","year":"2016","journal-title":"Mult Scler"},{"key":"key-10.4103\/1016-3190.237570-18","first-page":"878","volume-title":"A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease","author":"Weinshenker","year":"1999","journal-title":"Ann Neurol"},{"key":"key-10.4103\/1016-3190.237570-19","first-page":"487","volume-title":"Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder","author":"Bonnan","year":"2009","journal-title":"Mult Scler"},{"key":"key-10.4103\/1016-3190.237570-20","first-page":"858","volume-title":"Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica","author":"Merle","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"key-10.4103\/1016-3190.237570-21","first-page":"346","volume-title":"Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders","author":"Bonnan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.4103\/1016-3190.237570-22","first-page":"1","volume-title":"Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)","author":"Trebst","year":"2014","journal-title":"J Neurol"},{"key":"key-10.4103\/1016-3190.237570-23","first-page":"183","volume-title":"Maintenance plasma exchange therapy for steroid-refractory neuromyelitis optica","author":"Khatri","year":"2012","journal-title":"J Clin Apher"},{"key":"key-10.4103\/1016-3190.237570-24","first-page":"968","volume-title":"Low-dose corticosteroids reduce relapses in neuromyelitis optica: A retrospective analysis","author":"Watanabe","year":"2007","journal-title":"Mult Scler"},{"key":"key-10.4103\/1016-3190.237570-25","first-page":"627","volume-title":"Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica","author":"Kageyama","year":"2013","journal-title":"J Neurol"},{"key":"key-10.4103\/1016-3190.237570-26","first-page":"244","volume-title":"Neuromyelitis optica","author":"Carroll","year":"2010","journal-title":"Curr Treat Options Neurol"},{"key":"key-10.4103\/1016-3190.237570-27","first-page":"1219","volume-title":"Devic's neuromyelitis optica: A prospective study of seven patients treated with prednisone and azathioprine","author":"Mandler","year":"1998","journal-title":"Neurology"},{"key":"key-10.4103\/1016-3190.237570-28","first-page":"659","volume-title":"Azathioprine: Tolerability, efficacy, and predictors of benefit in neuromyelitis optica","author":"Costanzi","year":"2011","journal-title":"Neurology"},{"key":"key-10.4103\/1016-3190.237570-29","first-page":"1270","volume-title":"An open label study of the effects of rituximab in neuromyelitis optica","author":"Cree","year":"2005","journal-title":"Neurology"},{"key":"key-10.4103\/1016-3190.237570-30","first-page":"324","volume-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: Multicenter study of treatment efficacy","author":"Mealy","year":"2014","journal-title":"JAMA Neurol"},{"key":"key-10.4103\/1016-3190.237570-31","first-page":"31","volume-title":"Analysis of the treatment of neuromyelitis optica","author":"Torres","year":"2015","journal-title":"J Neurol Sci"},{"key":"key-10.4103\/1016-3190.237570-32","first-page":"180","volume-title":"An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica","author":"Collongues","year":"2016","journal-title":"Ther Adv Neurol Disord"},{"key":"key-10.4103\/1016-3190.237570-33","first-page":"1342","volume-title":"Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: A systematic review and meta-analysis","author":"Damato","year":"2016","journal-title":"JAMA Neurol"},{"key":"key-10.4103\/1016-3190.237570-34","first-page":"63","volume-title":"Mycophenolate mofetil, an inhibitor of inosine monophosphate dehydrogenase, causes a paradoxical elevation of GTP in erythrocytes of renal transplant patients","author":"Goldsmith","year":"2004","journal-title":"Clin Sci (Lond)"},{"key":"key-10.4103\/1016-3190.237570-35","first-page":"467","volume-title":"A neurologist's guide to safe use of immunomodulatory therapies","author":"Vodopivec","year":"2014","journal-title":"Semin Neurol"},{"key":"key-10.4103\/1016-3190.237570-36","first-page":"394","volume-title":"Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy","author":"Ayzenberg","year":"2013","journal-title":"JAMA Neurol"},{"key":"key-10.4103\/1016-3190.237570-37","first-page":"1302","volume-title":"Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: A pilot study","author":"Araki","year":"2014","journal-title":"Neurology"},{"key":"key-10.4103\/1016-3190.237570-38","unstructured":"Ocilizumab vs. Azathioprine in Neuromyelitis Optica Spectrum Disorders (TANGO). Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03350633. [Last accessed on 2017 Nov 22]."},{"key":"key-10.4103\/1016-3190.237570-39","first-page":"1233","volume-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","author":"Hillmen","year":"2006","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1016-3190.237570-40","first-page":"554","volume-title":"Eculizumab in AQP4-igG-positive relapsing neuromyelitis optica spectrum disorders: An open-label pilot study","author":"Pittock","year":"2013","journal-title":"Lancet Neurol"},{"key":"key-10.4103\/1016-3190.237570-41","unstructured":"A Double Blind Trial to Evaluate the Safety and Efficacy of Eculizumab in Relapsing NMO Patients (Prevent Study). Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01892345. [Last accessed on 2018 Jul 2]."},{"key":"key-10.4103\/1016-3190.237570-42","first-page":"143","volume-title":"RhC1INH: A new drug for the treatment of attacks in hereditary angioedema caused by C1-inhibitor deficiency","author":"Varga","year":"2011","journal-title":"Expert Rev Clin Immunol"},{"key":"key-10.4103\/1016-3190.237570-43","first-page":"1450","volume-title":"A role for humoral mechanisms in the pathogenesis of devic's neuromyelitis optica","author":"Lucchinetti","year":"2002","journal-title":"Brain"},{"key":"key-10.4103\/1016-3190.237570-44","first-page":"e5","volume-title":"Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica","author":"Levy","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"key-10.4103\/1016-3190.237570-45","first-page":"302","volume-title":"Retinoic acid-producing, ex-vivo-generated human tolerogenic dendritic cells induce the proliferation of immunosuppressive B lymphocytes","author":"Di","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"key-10.4103\/1016-3190.237570-46","first-page":"93","volume-title":"The interactions of dendritic cells with antigen-specific, regulatory T cells that suppress autoimmunity","author":"Tarbell","year":"2006","journal-title":"Semin Immunol"},{"key":"key-10.4103\/1016-3190.237570-47","first-page":"2758","volume-title":"Effective expansion of alloantigen-specific foxp3+ CD25+ CD4+ regulatory T cells by dendritic cells during the mixed leukocyte reaction","author":"Yamazaki","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key-10.4103\/1016-3190.237570-48","first-page":"e83575","volume-title":"Involvement of suppressive B-lymphocytes in the mechanism of tolerogenic dendritic cell reversal of type 1 diabetes in NOD mice","author":"Di","year":"2014","journal-title":"PLoS One"},{"key":"key-10.4103\/1016-3190.237570-49","unstructured":"Treatment of Multiple Sclerosis and Neuromyelitis Optica with Regulatory Dendritic Cell: Clinical Trial Phase 1 B. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT0228367. [Last accessed on 2017 Nov 7]."},{"key":"key-10.4103\/1016-3190.237570-50","first-page":"2026","volume-title":"Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients","author":"Giannoukakis","year":"2011","journal-title":"Diabetes Care"},{"key":"key-10.4103\/1016-3190.237570-51","first-page":"156","volume-title":"Development of dendritic cell-based immunotherapy for autoimmunity","author":"Hilkens","year":"2010","journal-title":"Int Rev Immunol"},{"key":"key-10.4103\/1016-3190.237570-52","first-page":"323","volume-title":"Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain","author":"Saadoun","year":"2012","journal-title":"Ann Neurol"},{"key":"key-10.4103\/1016-3190.237570-53","first-page":"535","volume-title":"Aquaporin 4 and neuromyelitis optica","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol"},{"key":"key-10.4103\/1016-3190.237570-54","first-page":"2306","volume-title":"Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica","author":"Zhang","year":"2013","journal-title":"J Clin Invest"},{"key":"key-10.4103\/1016-3190.237570-55","first-page":"145","volume-title":"Human immunoglobulin G reduces the pathogenicity of aquaporin-4 autoantibodies in neuromyelitis optica","author":"Ratelade","year":"2014","journal-title":"Exp Neurol"},{"key":"key-10.4103\/1016-3190.237570-56","first-page":"77","volume-title":"Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody","author":"Tradtrantip","year":"2013","journal-title":"Ann Neurol"},{"key":"key-10.4103\/1016-3190.237570-57","first-page":"314","volume-title":"Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica","author":"Tradtrantip","year":"2012","journal-title":"Ann Neurol"}],"container-title":["Tzu Chi Medical Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:40:09Z","timestamp":1786714809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tcmj.tcmj_102_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"alternative-id":["237570"],"URL":"https:\/\/doi.org\/10.4103\/tcmj.tcmj_102_18","relation":{},"ISSN":["1016-3190"],"issn-type":[{"value":"1016-3190","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}